Reversible phenotype in a mouse model of Hutchinson - Gilford progeria syndrome

Journal of Medical Genetics

Volumn 45, Issue 12, 2008, Pages 794-801

  Sagelius, H ^a   Rosengardten, Y ^a   Schmidt, E ^a   Sonnabend, C ^a   Rozell, B ^a   Erisson, Maria ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 5; CYTOKERATIN 6; DOXYCYCLINE; LAMIN A; LAMIN C; LORICRIN; PROTEIN FARNESYLTRANSFERASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; EPIDERMIS HYPERPLASIA; GENE EXPRESSION; GENE MUTATION; HISTOPATHOLOGY; HUTCHINSON SYNDROME; HYPERKERATOSIS; INCISOR; MOUSE; NONHUMAN; PHENOTYPE; PREMATURE AGING; PRIORITY JOURNAL; PROGERIA; REVERTANT; SEBACEOUS GLAND; TISSUE INJURY; TRANSGENIC MOUSE;

ANIMALS; CELL DIFFERENTIATION; DISEASE MODELS, ANIMAL; EPIDERMIS; HUMANS; IMMUNOHISTOCHEMISTRY; LAMIN TYPE A; LAMINS; MICE; MICE, TRANSGENIC; MUTATION; PHENOTYPE; PROGERIA;

ANIMALIA;

EID: 57349129516     PISSN: 00222593     EISSN: 14686244     Source Type: Journal    
DOI: 10.1136/jmg.2008.060772     Document Type: Article

References (30)

1. DeBusk FL. The Hutchinson-Gilford progeria syndrome. Report of 4 cases and review of the literature. J Pediatr 1972; 80:697-724.
2. Merideth MA, Gordon LB, Clauss S, Sachdev V, Smith AC, Perry MB, Brewer CC, Zalewski C, Kim HJ, Solomon B, Brooks BP, Gerber LH, Turner ML, Domingo DL, Hart TC, Graf J, Reynolds JC, Gropman A, Yanovski JA, Gerhard-Herman M, Collins FS, Nabel EG, Cannon- RO 3rd, Gahl WA, Introne WJ. Phenotype and course of Hutchinson-Gilford progeria syndrome. N Engl J Med 2008;358:598-604.
3. Burke B, Stewart CL. Life at the edge: the nuclear envelope and human disease. Nat Rev Mol Cell Biol 2002;3:575-85.
4. Fisher DZ, Chaudhary N, Blobel G. cDNA sequencing of nuclear lamins A and C reveals primary and secondary structural homology to intermediate filament proteins. Proc Natl Acad Sci U S A 1986; 83:6450-4.
5. Bergo MO, Gavino B, Ross J, Schmidt WK, Hong C, Kendall LV, Mohr A, Meta M, Genant H, Jiang Y, Wisner ER, Van Bruggen N, Carano RA, Michaelis S, Griffey SM, Young SG. Zmpste24 deficiency in mice causes spontaneous bone fractures, muscle weakness and a prelannin A processing defect. Proc Natl Acad Sci USA 2002;99:13049-54.
6. Hutchison CJ, Alvarez-Reyes M, Vaughan OA. Lamins in disease: why do ubiquitously expressed nuclear envelope proteins give rise to tissue-specific disease phenotypes? J Cell Sci 2001; 114:9-19.
7. Sasseville AM, Raymond Y. Lamin A precursor is localized to intranuclear foci. J Cell Sci 1995;108:273-85.
8. Stuurman N, Heins S, Aebi U. Nuclear lamins: their structure, assembly and interactions. J Struct Biol 1998;122:42-66.
9. De Sandre-Giovannoli A, Bernard R, Cau P, Navarro C, Amiel J, Boccaccio I, Lyonnet S, Stewart CL, Munnich A, Le Merrer M, Levy N. Lamin a truncation in Hutchinson-Gilford progeria. Science 2003; 300:2055.
10. Eriksson M, Brown WT, Gordon LB, Glynn MW, Singer J, Scott L, Erdos MR, Robbins CM, Moses TY, Berglund P, Dutra A, Pak E, Durkin S, Csolka AB, Boehnke M, Glover TW, Collins FS. Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature 2003;423:293-8.
11. Goldman RD, Shumaker DK, Erdos MR, Eriksson M, Goldman AE, Gordon LB, Gruenbaum Y, Khuon S, Mendez M, Varga R, Collins FS. Accumulation of mutant lamin A causes progressive changes in nuclear architecture in Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A 2004;101:8963-8.
12. Alsina M, Fonseca R, Wilson EF, Belle AN, Gerbino E, Price-Troska T, Overton RM, Ahmann G, Bruzek LM, Adjei AA, Kaufmann SH, Wright J J, Sullivan D, Djulbegovic B, Cantor AB, Greipp PR, Dalton WS, Sebti SM. Farnesyltransferase inhibitor tipifamib is well tolerated, induces stabilisation of disease and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood 2004;103:3271-7.
13. Kim ES, Kies MS, Fossella FV, Glisson BS, Zalknoen S, Statkevich P, Munden RF, Summey C, Pisters KM, Papadimitrakopoulou V, Tighiouart M, Rogatko A, Khuri FR. Phase II study of the farnesyltransferase inhibitor lonafamib with paclitaxel in patients with taxane-refractory/resistant non-small cell lung carcinoma. Cancer 2005;104:561-9.
14. Sebti SM, Der CJ. Opinion: Searching for the elusive targets of farnesyltransferase inhibitors. Nat Rev Cancer 2003; 3:945-51.
15. Yang SH, Bergo MO, Toth JI, Giao X, Hu Y, Sandoval S, Meta M, Bendale P, Gelb MH, Young SG, Fong LG. Blocking protein farnesyltransferase improves nuclear blebbing in mouse fibroblasts with a targeted Hutchinson-Gilford progeria syndrome mutation. Proc Natl Acad Sci U S A 2005;102:10291-6.
16. Capell BC, Erdos MR, Madigan JP, Fiordalisi JJ, Varga H, Conneely KN, Gordon LB, Der CJ, Cox AD, Collins FS. Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A 2005;102:12879-84.
17. Glynn MW, Glover TW. Incomplete processing of mutant lamin A in Hutchinson-Gilford progeria leads to nuclear abnormalities, which are reversed by farnesyltransferase inhibition. Hum Mol Genet 2005; 14:2959-69.
18. Mallampalli MP, Huyer G, Bendale P, Gelb MH, Michaelis S. Inhibiting farnesylation reverses the nuclear morphology defect in a HeLa cell model for Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A 2005;102:14416-421.
19. Pan Y, Garg A, Agarwal AK. Mislocalization of prelamin A Tyr646Phe mutant to the nuclear pore complex in human embryonic kidney 293 cells. Biochem Biophys Res Commun 2007;355:78-84.
20. Toth JI, Yang SH, Oiao X, Beigneux AP, Gelb MH, Moulson CL, Miner JH, Young SG, Fong LG. Blocking protein farnesyltransferase improves nuclear shape in fibroblasts from humans with progeroid syndromes. Proc Natl Acad Sci U S A 2005;102:12873-8.
21. Fong LG, Frost D, Meta M, Ciao X, Yang SH, Coffinier C, Young SG. A protein farnesyltransferase inhibitor ameliorates disease in a mouse model of progeria. Science 2006;311:1621-3.
22. Yang SH, Meta M, Ciao X, Frost D, Bauch J, Coffinier C, Majumdar S, Bergo MO, Young SG, Fong LG. A farnesyltransferase inhibitor improves disease phenotypes in mice with a Hutchinson-Gilford progeria syndrome mutation. J Clin Invest 2006;116:2115-21.
23. Huang S, Chen L, Libina N, Janes J, Martin GM, Campisi J, Oshima J. Correction of cellular phenotypes of Hutchinson-Gilford Progeria cells by RNA interference. Hum Genet 2005;118:444-50.
24. Scaffidi P, Misteli T, Reversal of the cellular phenotype in the premature aging disease Hutchinson-Gilford progeria syndrome. Nat Med 2005;11:440-5.
25. Sagelius H, Rosengardten Y, Hanif M, Erdos MR, Rozell B, Collins FS, Eriksson M. Targeted transgenic expression of the mutation causing Hutchinson-Gilford progeria syndrome leads to proliferative and degenerative epidermal disease. J Cell Sci 2008;121:969-78.
26. Diamond I, Owolabi T, Marco M, Lam C, Glick A. Conditional gene expression in the epidermis of transgenic mice using the tetracycline-regulated transactivators tTA and rTA linked to the keratin 5 promoter. J Invest Dermatol 2000;115:788-94.
27. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008;214:199-210.
28. Long PH, Leininger JR. Teeth, In: Maronpot FIR, Boorman GA, Gaul BW, eds. Pathology of the mouse: reference and atlas. St Louis: Cache River Press, 1999:13-28.
29. Kerley MA, Kollar EJ. In vitro inhibition of mouse dental development by tetracycline. J Exp Zool 1978;203:89-98.
30. Havenaar R, Meijer JC, Morton DB, Hitskes-Hoitinga J, Zwart P. Biology and husbandry of laboratory animals. In: Van Zutphen LFM, Baumans V, Beynen AC, eds. Principles of laboratory animal science Amsterdam: Elsevier, 2001:19-76.